OBJECTIVE: To observe the effect of the polyglycol (PEG) modification of trimeric ? peptide(?3) on it’s anti-metastasis ability. METHODS: Using adhesion test to study the effects of ?3 and ?3-PEG on the adhesion of tumor cells to FN. Using artificial basal membrane to study the effects of ?3 and ?3-PEG on the invasion and recombination of basal membrane of tumor cells. RESULTS: Comparing to negative control,?3 and ?3-PEG could both inhibit the adhesion of SMMC-7721 and HCCLM6 tumor cells to FN with time-dependently(P

Objective To Study the correlation factors for diabetes pathogenesis of Uygur Nationality in Urumuqi.Methods A cluster sampling was done in 1002 Uygur people aged 25 to 74 years in a part of working units and living area in Urumuqi.All the people received 75g oral glucose tolerance test.Waist and hip circumference,blood pressure,height and body weight were measured.A questionnaire involved in the family history,diet,physical activity and the expenditure on diet was taken.Results(1)63% of the people was male,while 37% was female in our study.The constituent ratio of age was as following:25y～,23.08%;35y～,36.90%;45y～,19.64%;55y～,14.86%and 65y～,5.51%.(2)The prevalence of DM in the study was 14.69%,the abnormality of glucose metabolism was 29.89%.(3)The correlation factors of diabetes were family history of diabetes(OR 0.59),age(OR 0.83),high blood pressure(OR 0.912),waist-to-hip ratio(OR 3.851)and financial spending on diet(OR 5.279) in logistic regression analysis.Conclusions Diabetes-correlated factors are high financial spending on food especially meat products and little cellulose intake,high waist-to-hip ratio.To decrease the prevalence rate of diabetes in Uygur nationality,it is most important to change the diet habit and decrease intra-abdominal fat deposition

Chronic Disease ; therapy ; Drugs, Chinese Herbal ; therapeutic use ; Heart Failure ; drug therapy ; Humans ; Medicine, Chinese Traditional

Female ; Humans ; Maternal Health Services ; Maternal Mortality ; Pregnancy

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; complications ; Humans ; Thromboembolism ; etiology ; prevention & control

Tremendous success has emerged in chimeric antigen receptor (CAR)-T cell therapy over the past few years, especially in leukemia and lymphoma. The first CAR-T cell product might be available in America in 2017 due to the emergence of the critical results. This paper focused on the key data presented at the 58th American Society of Hematology Annual Meeting.

Objective:To investigate and analyze the rational use of anti-tumor immune enhancement drugs in our hospital. Meth-ods:The annual use data of anti-tumor immune enhancement drugs in our hospital in 2015 were collected, and then statistically ana-lyzed and evaluated combing with the medical history information. Results: There were 12 varieties and 19 specifications of adjuvant anti-tumor immune enhancement drugs in our hospital, which accounted for 15. 87% of the total sum. Totally 25 481 patients used ad-juvant anti-tumor immune enhancement drugs, which occupied 29. 84% of the total medicine afford. The adjuvant anti-tumor immune enhancement drugs showed lots of irrational use in clinics, and the main irrationity was overuse and off-label use. Conclusion: It is necessary to strengthen prescription evaluation for anti-tumor immune enhancement drugs, which needs controlled and rational use.

BACKGROUND:It is reported that vitamin C can induce bone marrow mesenchymal stem cel s differentiating into osteoblasts, and promote bone repair and regeneration. However, vitamin C solution is unstable, so a carrier is necessary. OBJECTIVE:To observe the loading and control ed-release abilities of calcium phosphate used as the carrier ofvitamin C. METHODS:Calcium phosphate particles loaded with vitamin C were fabricated using chemical precipitation method, and the final concentration of vitamin C was 0, 0.1, 2 and 4 mmol/L, respectively. The drug-loaded capacity was detected. The release of vitamin from calcium phosphate nanoparticles in the simulate body fluid and ultrasonic environment was respectively evaluated. MC3T3-E1 cel s were co-cultured with calcium phosphate nanoparticles loaded with 2 mmol/L vitamin C, or calcium phosphate nanoparticles only. The cel proliferation was detected at 1, 3, 5 and 7 days of culture, and the alkaline phasphatase activity was detected at 1, 5, 10 and 15 days of culture. RESULTS AND CONCLUSION:The drug-loaded contents of calcium phosphate nanoparticles loading 0, 0.1, 2 and 4 mmol/L vitamin C were (59.9±5.4)%, (87.2±1.2)%and (28.4±26.3)%, respectively. Under normal environment, al samples could release vitamin C persistently, but the initial release speed of the particles carrying 0.1 and 2 mmol/L vitamin C was lower than that of particles carrying 4 mmd/L vitamin. Under ultrasonic environment, 2 mmol/L vitamin C-loaded calcium phosphate particles exhibited a quick release speed firstly that reached 5-15%, fol owed by a slow release speed. When ultrasonic powers kept at 75, 105 and 150 W, the release duration of vitamin C was 220, 340 and 260 minutes, respectively. MC3T3-E1 cel proliferation did not change after co-cultured with 2 mmol/L vitamin C-loaded calcium phosphate particles but the alkaline phosphatase activity was improved. These results suggest that calcium phosphate particles can be used as the carrier of vitamin C.

Side population cells (SPs) are selected by the efflux features of fluorescent dye Hoechst33342.SPs have the characteristics of cancer stem cells,and play an extremely important role in the occurrence and development of tumors.At present,the SPs in common types of malignant tumor have been studied extensively at home and abroad.The study of SPs may shed some light on the diagnosis and treatment of cancer.

Advances in clinical transformation research has facilitated discovery of a number of novel somatic mutations and aberrant intracellular signaling pathways involved in malignant proliferative B-cell lymphoma.Meanwhile,small molecular inhibitors targeting those mutation genes or signaling pathways have also been shown to be effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma.This paper reviewed important discoveries in clinical transformation research in lymphoma field in 2013.